Skip to main content
. Author manuscript; available in PMC: 2018 Jan 9.
Published in final edited form as: Clin Infect Dis. 2015 Mar 16;61(2):157–168. doi: 10.1093/cid/civ220

Figure 2.

Figure 2

Incremental cost-effectiveness by liver fibrosis score as measured by METAVIR score. Abbreviations: ICER, incremental cost-effectiveness ratio; PRS/SR, pegylated interferon, ribavirin and sofosbuvir for genotypes 1 and 4, and sofosbuvir and ribavirin for genotypes 2 and 3; SS/SR, sofosbuvir and simeprevir for genotypes 1 and 4, and sofosbuvir and ribavirin for genotypes 2 and 3.